Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
03/2010
03/17/2010CN101669936A Drug combination containing pratensein and application thereof in drugs
03/17/2010CN101669935A Drug combination containing prunetin and application thereof in drugs
03/17/2010CN101669934A Suppressive activity of mango aglycone on PTP1B and application thereof
03/17/2010CN101669931A Application of long effective curcumin derivative in preparing anti-tumor disease drug
03/17/2010CN101669925A Dry powder inhalation, preparation method and application thereof
03/17/2010CN101669915A Oridonin dry emulsion and preparation method thereof
03/17/2010CN101669908A Preparing method of taxanes substance preparation with nanostructure
03/17/2010CN101669907A Oridonin emulsion
03/17/2010CN101669900A Polymeric delivery formulations of leuprolide with improved efficacy
03/17/2010CN101669899A Sustained-release implant taking maize protein as main framework material or matrix and use thereof
03/17/2010CN101669898A Medicinal preparation for injective administration and preparation method thereof
03/17/2010CN100594212C Polymorphic form of N-[(R)-2,3-dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-benzamide
03/16/2010US7678919 Method for producing pentacyclic taxans
03/16/2010US7678918 Induce the biosynthesis of cytokines such as interferon and tumor necrosis factor; antiviral and antitumor agents
03/16/2010US7678887 Identification and cloning of a novel human gene, RET16, involved in the intracellular signaling cascade
03/16/2010US7678834 Substituted 4-aminocyclohexanol compounds
03/16/2010US7678812 Aminotetralin-derived urea modulators of vanilloid VR1 receptor
03/16/2010US7678811 An urea compounds containing a pyridine, quinoline, or isoquinoline functionality; p38 mediated diseases such as inflammation and VEGF mediated diseases such as angogenesis disorders
03/16/2010US7678804 Pyrimidine derivatives for treatment of hyperproliferative disorders
03/16/2010US7678802 Voltage gated sodium and calcium channel inhibitors
03/16/2010US7678779 Methods for the administration of amifostine and related compounds
03/16/2010US7678777 increase a person immunity by oral administering a mixture including a dextran, promoting the cell growth and colonizing in the intestine of a subject without supplying L. casei subsp. casei at all times
03/16/2010US7678765 Synthetic methods for aplidine and new antitumoral derivatives, methods of making and using them
03/16/2010US7678759 Diagnosis and treatment of neuroectodermal tumors
03/16/2010US7678758 For enhancing T cell response to tumour cells
03/16/2010US7678552 Method for selecting therapeutic agents for cancer treatment
03/16/2010US7678549 Polyphenol inhibition of nucleoside diphosphate kinase-B activity and cancer metastasis
03/16/2010US7678372 Tyrosine kinase inhibitors; anticancer agents; genetic engineered protein
03/16/2010CA2512683C Tricyclic compounds protein kinase inhibitors for enhancing the efficacy of anti-neoplastic agents and radiation therapy
03/16/2010CA2438646C Pyrimidine derivatives for inhibition of cell-proliferation
03/16/2010CA2437718C Carboline derivatives
03/16/2010CA2436724C Use of inhibitors of dipeptidyl peptidase iv (dp iv) in combination with inhibitors of alanyl-aminopeptidase (apn)
03/16/2010CA2396965C Piperidine- and piperazine substituted n-hydroxyformamides as inhibitors of metalloproteinases
03/16/2010CA2372575C Bradykinin receptor antagonists
03/16/2010CA2358420C New compounds for the treatment of cancer
03/16/2010CA2336846C Use of cysteine derivatives for the preparation of a medicament intended to treat pathologies which result from the formation of the heterotrimeric g protein
03/16/2010CA2087817C 3'-derivatized oligonucleotide analogs with non-nucleotidic groupings, their preparation and use
03/12/2010CA2639562A1 Use of cysteine-rich whey derived protein in patients receiving chemotherapy or radiotherapy to improve patient survival
03/11/2010WO2010028259A2 9-aminonoscapine and its use in treating cancers, including drug- resistant cancers
03/11/2010WO2010028187A2 Methods and compositions for the treatment of cancer
03/11/2010WO2010028156A2 Dual modality detection of apoptosis
03/11/2010WO2010028116A1 Macrocyclics pyrimidines as aurora kinase inhibitors
03/11/2010WO2010028093A2 Use of a truncated elf-5a1 polynucleotide to induce apoptosis in cancer cells
03/11/2010WO2010028066A2 Cd133 epitopes
03/11/2010WO2010028058A1 2, 4-disulfonyl pheny tert-butyl nitrone for the treatment of gliomas
03/11/2010WO2010028051A2 Substituted heterocyclic mercaptosulfonamide metalloprotease inhibitors
03/11/2010WO2010028047A1 Erodible embolization material
03/11/2010WO2010027981A1 Multispecific antibodies
03/11/2010WO2010027848A2 Forms of lapatinib compounds and processes for the preparation thereof
03/11/2010WO2010027500A1 Aminotriazolopyridines and their use as kinase inhibitors
03/11/2010WO2010027488A2 Monoclonal antibodies
03/11/2010WO2010027458A2 Pdk inhibitor compounds and methods of use thereof
03/11/2010WO2010027428A1 Platinum ( iv) complexes for use in dual mode pharmaceutical therapy
03/11/2010WO2010027424A2 9-substituted phenanthrene based tylophorine derivatives
03/11/2010WO2010027294A1 Composition for treating dysplastic changes in the uterine cervix
03/11/2010WO2010027094A1 NKT CELL-DERIVED iPS CELLS AND NKT CELLS DERIVED THEREFROM
03/11/2010WO2010027002A1 Ring-fused morpholine derivative having pi3k-inhibiting activity
03/11/2010WO2010026993A1 Method for improving absorbability of preparation, and preparation having improved absorbability
03/11/2010WO2010026711A1 Platinum complex and medical compound containing same
03/11/2010WO2010026660A1 Rna capable of inhibiting expression of zfat gene
03/11/2010WO2010026638A1 Hyperthermic therapy kit for malignant tumor comprising anti-regulatory-t-cell antibody and magnetic microparticle, and hyperthermic therapy using the kit
03/11/2010WO2010026291A1 Materials and methods for inhibiting cancer cell invasion related to fgfr4
03/11/2010WO2010026262A1 Pyrido [5, 4-d] pyrimidines as cell proliferation inhibitors
03/11/2010WO2010026238A1 Combination preparation for treating cancer
03/11/2010WO2010026124A1 Picolinamide derivatives as kinase inhibitors
03/11/2010WO2010026122A1 Heterocyclic pim-kinase inhibitors
03/11/2010WO2010026094A1 Detection and use of low molecular-weight modulators of the cold-menthol receptor trpm8
03/11/2010WO2010025872A2 Alfa-carboline inhibitors of npm-alk, ret, and bcr-abl
03/11/2010WO2010025621A1 Extracts of flavonoids-containing traditional chinese medicine, extraction method, pharmaceutical composition and application thereof
03/11/2010WO2010025589A1 Long acting curcumine derivates and preparation method thereof
03/11/2010WO2010007114A3 Heterocyclyl carbonic acid amides as antiproliferative agents, pdkl inhibitors
03/11/2010WO2010006755A3 Cyclic polyamines for binding phosphatidylserine
03/11/2010WO2010004512A3 Dicarba-analgues of octreotide
03/11/2010WO2010004438A3 Lm-antibodies, functional fragments, lm-1 target antigen, and methods for making and using same
03/11/2010WO2010004197A3 Pyridino-pyridinone derivatives, preparation thereof, and therapeutic use thereof
03/11/2010WO2009158431A3 Pyrimidine derivatives as kinase inhibitors
03/11/2010WO2009156182A3 Uracil derivatives and use thereof
03/11/2010WO2009151920A9 Hepsin inhibitors
03/11/2010WO2009143372A3 Compositions comprising a-raf, b-raf, and c-raf sirna and methods of use thereof
03/11/2010WO2009140326A3 Microfluidic isolation of tumor cells or other rare cells from whole blood or other liquids
03/11/2010WO2009126651A9 Mat ii subunit rnai and therapeutic methods using same
03/11/2010WO2009118567A3 Pyrimidines, triazines and their use as kinase inhibitors
03/11/2010WO2009118411A3 3,4-dihydro-2h-pyrazino[1,2-a]indol-1-one derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
03/11/2010WO2009100176A3 Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor
03/11/2010WO2009095583A3 Use of aminopeptidase inhibitors or azaindole compounds for preventing or treating cancerous metastases from epithelial origin
03/11/2010WO2009050486A3 F0xp3 : nfat inhibitor peptides for the treatment of cancer
03/11/2010WO2009026446A9 Hdac inhibitors
03/11/2010US20100063163 Extract Solution Comprising a B-Cryptoxanthin Component and Food and Drink Soaps
03/11/2010US20100063162 Method for predicting efficacy of rar-alpha agonist
03/11/2010US20100063158 Crystalline form III of agomelatine, a process for its preparation and pharmaceutical compositions containing it
03/11/2010US20100063145 Acid containing oxaliplatin formulations
03/11/2010US20100063144 Compounds and uses thereof
03/11/2010US20100063137 Cytotoxin Compound And Method of Isolation
03/11/2010US20100063131 Prompt nucleic acid delivery carrier composition
03/11/2010US20100063120 Imidazolidine Derivatives, Uses Therefor, Preparation Thereof and Compositions Comprising Such
03/11/2010US20100063118 Hydantoins Having RNase Modulatory Activity
03/11/2010US20100063115 5-(1,3,4-oxadiazol-2-yl)-1h-indazole and 5-(1,3,4-thiadiazol-2-yl)-1h-indazole derivatives as sgk inhibitors for the treatment of diabetes
03/11/2010US20100063114 Inhibitors of protein prenyltransferases
03/11/2010US20100063112 Polymorph iii of 4-[4-(amino)-3-fluorophenoxy]-n-methylpyridine-2-carboxamide
03/11/2010US20100063109 Thiadiazolidinone derivatives
1 ... 716 717 718 719 720 721 722 723 724 725 726 727 728 729 730 731 732 733 734 735 736 ... 2211